CytRx's Clinical Advisory Board includes experts in the fields of drug development, medicine, pharmacology, and toxicology.

Dr. David R. Parkinson is an internationally known oncology authority who formerly held senior executive positions in oncology research and drug development at Biogen Idec, Amgen and Novartis AG. He has served as Acting Associate Director of the Cancer Therapy Evaluation Program at the National Cancer Institute and is a past Chairman of the U.S. Food & Drug Administration (FDA) Biologics Advisory Committee. Dr. Parkinson was recently elected to the Board of Directors of the American Association of Cancer Research. Dr. Parkinson is currently the President and CEO of Nodality, a biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and decision making. Before joining Nodality, Dr. Parkinson was the Senior Vice President, Oncology Research and Development at Biogen Idec, where he oversaw all oncology discovery research efforts and the development of its oncology pipeline. Prior to that, he served as Vice President, Oncology Development, at Amgen and Vice President, Global Clinical Oncology Development, at Novartis. From 1990 to 1997 Dr. Parkinson was affiliated with the National Cancer Institute, where he served as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program. He has held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine. He received his M.D., as gold medalist, from the University of Toronto Faculty of Medicine in 1977, with Internal Medicine and Hematology/Oncology training in Montreal at McGill University and in Boston at New England Medical Center. Dr. Parkinson is a past President of the International Society of Biological Therapy, and past Editor of the Journal of Immunotherapy. He currently serves on the National Cancer Policy Forum of the Institute of Medicine and is a member of the FDA's Science Board. He was recently elected to the Board of Directors of the American Association of Cancer Research (AACR), and continues to serve as Chairman of the AACR Finance Committee.

Dr. Virinder Nohria is a board-certified neurologist with special qualifications in child neurology. He received his medical training at the University of Cambridge in England. His postgraduate training was completed in the U.K. and the U.S. He also holds a Ph.D. degree in Neuropharmacology. He has over 15 years of experience in the field of international drug development in large and small pharmaceutical and biotechnology companies. He worked for Eli Lilly and Company as well as UCB Pharma. Most recently, he was Vice President and Chief Medical Officer of Xcel Pharmaceuticals, a specialty pharmaceutical company that was acquired by Valeant International in 2005 for an enterprise value of nearly $300 million. At present, Dr. Nohria acts as an independent consultant to the pharmaceutical and biotechnology industry, including investors, venture capital groups and investment banks. He is a non-executive director of Allergy Therapeutics plc (AIM: AGY), a UK based specialist pharmaceutical company. He is also a founder and acting chief medical officer of Alaven Pharmaceuticals inc., a privately held speciality pharma company specializing in Women’s Health, GI, and anemia, with over 130 employees. He has published more than 40 scientific articles and book chapters. He was on the faculty of the medical school at the University of Virginia and was an adjunct faculty member of Emory University School of Medicine in Atlanta.

Dr. Sue Griffith received her medical training at the University of London in the UK and is a member of the Royal College of Physicians of London. She also holds a Ph.D. in Pharmacology. She has more than 18 years of drug development experience in the pharmaceutical industry (large and mid-sized pharma and biotech companies), firstly in the U.K. and for the last 14 years in the U.S., covering a wide variety of therapeutic areas. She has worked as a clinical pharmacologist for DuPont Pharmaceuticals, Procter & Gamble Pharmaceuticals, and Wellcome. Most recently, she was Senior Director, Clinical Development and Head of the Clinical Pharmacology & Pharmacokinetics Group at Elan Pharmaceuticals Inc, in San Diego. Dr. Griffith now acts as an independent consultant specializing in early phase development and clinical pharmacology strategy through to regulatory filings and post-approval. She provides services to pharmaceutical and biotechnology companies of all sizes, venture capital companies, Contract Research Organizations, consulting companies and other independent consultants.

Dr. Cynthia Rask is a board-certified neurologist who completed her neurology residency at the University of Rochester. She has over 15 years of experience in drug development including seven years with the FDA (5 as Director, Division of Clinical Evaluation and Pharmacology/Toxicology in the Office of Cellular, Tissue and Gene Therapies).  She has also worked for Abbott Laboratories and Genetech Inc. At present, Dr. Rask acts as an independent consultant to the pharmaceutical and biotechnology industry providing neurologic and regulatory expertise for clinical development programs as well as identifying and mapping regulatory strategies for their programs.